Applera and Beckman Coulter Announce Terms of Settlement of Legal Disputes regarding PCR technology
As part of the settlement, the parties will grant royalty-bearing licenses to each other. Beckman Coulter will grant Applera licenses to its patents for replaceable gels for capillary electrophoresis instruments and DNA sequencers and to its patent for a heated lid for thermal cyclers; Applera will grant Beckman Coulter licenses conferring rights in the diagnostics market to its patents for nucleic acid sequencing and real time PCR thermalcycling. Additionally, Applera's Applied Biosystems Group will make a $35 million special payment to Beckman Coulter on signing for release of any and all claims of infringement relating to DNA sequencer and thermal cycler products. Beckman Coulter will make a $20 million payment over 10 quarters to Applera's Celera Genomics Group for rights in the diagnostics market to the referenced Applera technology. The U.S. District Court for the Central District of California has said it will stay its proceedings for 90 days pending completion of definitive agreements based on these terms.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.